-
★
SARS-CoV-2-specific immune responses and clinical outcomes after COVID-19 vaccination in patients with immune-suppressive disease
(Hinzugefügt: 05.08.2023 um 11:49 Uhr)
https://www.nature.com/articles/s41591-023-02414-4
-
★
Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2
(Hinzugefügt: 10.04.2023 um 14:15 Uhr)
https://www.nature.com/articles/s41564-023-01359-1
-
★
Comparison of SARS-CoV-2 Antibody Response After 2-Dose mRNA-1273 vs BNT162b2 Vaccines in Incrementally Immunosuppressed Patients
(Hinzugefügt: 27.05.2022 um 08:13 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2792369
-
★
Longitudinal analysis of antibody trajectories and humoral responses to a third dose of mRNA vaccines against SARS-CoV-2 in patients with a history of anti-CD20 therapy (RituxiVac 2.0)
(Hinzugefügt: 22.11.2021 um 08:50 Uhr)
https://www.medrxiv.org/content/10.1101/2021.11.19.21266572v1
-
★
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
(Hinzugefügt: 19.11.2021 um 16:04 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00351-9/fulltext
-
★
STIKO-Empfehlung zur COVID-19-Impfung: Personen mit Immundefizienz
(Hinzugefügt: 12.10.2021 um 10:50 Uhr)
https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/39_21.pdf?__blob=publicationFile
-
★
Study identifies predictors of COVID-19 vaccine response in rituximab-treated patients
(Hinzugefügt: 03.10.2021 um 08:08 Uhr)
https://rheumatology.medicinematters.com/covid-19/vaccination/rituxivac-predictors-of-response/19656500
-
★
STIKO-Empfehlung zur COVID-19-Impfung bei Personen mit Immundefizienz und die dazugehörige wissenschaftliche Begründung
(Hinzugefügt: 03.10.2021 um 08:07 Uhr)
https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/Ausgaben/39_21.pdf?__blob=publicationFile
-
★
Antibody kinetics in patients with rheumatic diseases after SARS-CoV-2 mRNA vaccination
(Hinzugefügt: 29.09.2021 um 09:57 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00282-4/fulltext
-
★
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity FREE
(Hinzugefügt: 03.08.2021 um 09:09 Uhr)
https://ard.bmj.com/content/early/2021/07/19/annrheumdis-2021-220781
-
★
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case SeriesFREE
(Hinzugefügt: 23.06.2021 um 17:54 Uhr)
https://www.acpjournals.org/doi/10.7326/L21-0282
-
SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity
(Hinzugefügt: 07.04.2023 um 17:47 Uhr)
https://www.nature.com/articles/s41467-023-36686-8
-
Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study
(Hinzugefügt: 30.12.2022 um 15:14 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00330-7/fulltext
-
Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer
(Hinzugefügt: 30.12.2022 um 15:13 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2799615
-
Comparison of the safety and immunogenicity of the BNT-162b2 vaccine and the ChAdOx1 vaccine for solid organ transplant recipients: a prospective study
(Hinzugefügt: 14.11.2022 um 13:27 Uhr)
https://bmcinfectdis.biomedcentral.com/articles/10.1186/s12879-022-07764-x
-
SARS-CoV-2 mRNA vaccinations fail to elicit humoral and cellular immune responses in patients with multiple sclerosis receiving fingolimod
(Hinzugefügt: 26.10.2022 um 15:09 Uhr)
https://jnnp.bmj.com/content/93/9/960
-
COVID-19-Auffrischimpfung: Humorale Immunantwort bei Krebspatienten von Behandlungsart abhängig
(Hinzugefügt: 26.10.2022 um 14:29 Uhr)
https://www.aerzteblatt.de/nachrichten/138036/COVID-19-Auffrischimpfung-Humorale-Immunantwort-bei-Krebspatienten-von-Behandlungsart-abhaengig
-
Analysis of Postvaccination Breakthrough COVID-19 Infections Among Adults With HIV in the United States
(Hinzugefügt: 24.06.2022 um 09:39 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2793102
-
Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study
(Hinzugefügt: 25.05.2022 um 15:23 Uhr)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(22)00202-9/fulltext
-
Immunological findings in a group of individuals who were non-responders to standard two-dose SARS-CoV-2 vaccines
(Hinzugefügt: 09.05.2022 um 09:07 Uhr)
https://www.biorxiv.org/content/10.1101/2022.05.05.490815v1
-
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
(Hinzugefügt: 11.04.2022 um 08:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S1535610822001477
-
Augmentation of humoral and cellular immune responses after third-dose SARS-CoV-2 vaccination and viral neutralization in myeloma patients
(Hinzugefügt: 11.04.2022 um 08:47 Uhr)
https://www.sciencedirect.com/science/article/pii/S1535610822001477
-
T-cell response to 3 doses of Sars-Cov2 BNT162b2 Pfizer vaccine in long term rituximab treated patients
(Hinzugefügt: 22.03.2022 um 12:03 Uhr)
https://www.sciencedirect.com/science/article/pii/S0953620522000425
-
Humoral responses after second and third SARS-CoV-2 vaccination in patients with immune-mediated inflammatory disorders on immunosuppressants: a cohort study
(Hinzugefügt: 22.03.2022 um 11:27 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(22)00034-0/fulltext
-
Evaluation of Antibody Response to SARS-CoV-2 mRNA-1273 Vaccination in Patients With Cancer in Florida
(Hinzugefügt: 11.03.2022 um 10:40 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2790099
-
Immunogenicity of a Third COVID-19 mRNA Vaccine Dose in PID Patients with Functional B-cell Defects
(Hinzugefügt: 08.03.2022 um 11:12 Uhr)
https://www.jaci-inpractice.org/article/S2213-2198(22)00231-8/fulltext#relatedArticles
-
Immunogenicity of a Third COVID-19 mRNA Vaccine Dose in PID Patients with Functional B-cell Defects
(Hinzugefügt: 08.03.2022 um 11:11 Uhr)
https://www.jaci-inpractice.org/article/S2213-2198(22)00231-8/pdf
-
Diminishing Immune Responses against Variants of Concern in Dialysis Patients 4 Months after SARS-CoV-2 mRNA Vaccination
(Hinzugefügt: 06.03.2022 um 20:33 Uhr)
https://wwwnc.cdc.gov/eid/article/28/4/21-1907_article
-
COVID Auffrischimpfung für Menschen mit Rheuma
(Hinzugefügt: 21.02.2022 um 16:37 Uhr)
https://dgrh.de/Start/Wissenschaft/Forschung/COVID-19/Stellungnahme-Covid-19-Auffrischimpfung.html
-
Antibody response against SARS-CoV-2 Delta and Omicron variants after third-dose BNT162b2 vaccination in allo-HCT recipients
(Hinzugefügt: 19.02.2022 um 13:21 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(22)00057-5
-
Antigen Specific Humoral and Cellular Immunity Following SARS-CoV-2 Vaccination in ANCA-Associated Vasculitis Patients Receiving B-Cell Depleting Therapy
(Hinzugefügt: 17.02.2022 um 07:16 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2022.834981/full?utm_source=S-TWT&utm_medium=SNET&utm_campaign=ECO_FIMMU_XXXXXXXX_auto-dlvrit
-
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
(Hinzugefügt: 11.01.2022 um 10:18 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00394-5/fulltext
-
SARS-CoV-2 Antibody Response to 2 or 3 Doses of the BNT162b2 Vaccine in Patients Treated With Anticancer Agents
(Hinzugefügt: 11.01.2022 um 10:15 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2788011
-
Immune responses following third COVID-19 vaccination are reduced in patients with hematological malignancies compared to patients with solid cancer
(Hinzugefügt: 11.01.2022 um 10:10 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00666-8
-
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
(Hinzugefügt: 29.12.2021 um 17:50 Uhr)
https://www.sciencedirect.com/science/article/pii/S2665991321003945
-
Anti-CD20 monoclonal antibodies inhibit seropositive response to Covid-19 vaccination in Non-Hodgkin lymphoma patients within six months after treatment
(Hinzugefügt: 29.12.2021 um 17:49 Uhr)
https://www.exphem.org/article/S0301-472X(21)00855-9/fulltext
-
Comparison of SARS-CoV-2 Antibody Response 4 Weeks After Homologous vs Heterologous Third Vaccine Dose in Kidney Transplant Recipients
(Hinzugefügt: 29.12.2021 um 15:57 Uhr)
https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2787200
-
Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study
(Hinzugefügt: 29.12.2021 um 15:55 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00394-5/fulltext
-
SARS-CoV-2: Nierentransplantierte reagieren nur schwach auf Booster
(Hinzugefügt: 23.12.2021 um 16:53 Uhr)
https://www.aerzteblatt.de/nachrichten/130365/SARS-CoV-2-Nierentransplantierte-reagieren-nur-schwach-auf-Booster
-
Antibody Response to 2-Dose Sars-Cov-2 mRNA Vaccine in Allogeneic Hematopoietic Cell Transplant Recipients
(Hinzugefügt: 18.12.2021 um 15:04 Uhr)
https://eventpilot.us/web/page.php?page=Inthtml&project=ASH21&id=149495P
-
COVID-19 Vaccine Antibody Responses in Patients Treated with B-Cell Agents Depend on B-Cell Counts at Time of Vaccine
(Hinzugefügt: 18.12.2021 um 15:03 Uhr)
https://acrabstracts.org/abstract/covid-19-vaccine-antibody-responses-in-patients-treated-with-b-cell-agents-depend-on-b-cell-counts-at-time-of-vaccine/
-
Robust T cell responses in anti-CD20 treated patients following COVID-19 vaccination: a prospective cohort study
(Hinzugefügt: 18.12.2021 um 15:01 Uhr)
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciab954/6430423
-
„Mehrere Impfversuche bei initialen Non-Respondern machen“
(Hinzugefügt: 18.12.2021 um 14:57 Uhr)
https://www.aerzteblatt.de/nachrichten/129957/Mehrere-Impfversuche-bei-initialen-Non-Respondern-machen
-
Schlechtes Ansprechen auf Coronaimpfung vor allem bei Non-Hodgkin-Lymphom und aktiver Therapie
(Hinzugefügt: 17.12.2021 um 13:59 Uhr)
https://www.aerzteblatt.de/nachrichten/130058/Schlechtes-Ansprechen-auf-Coronaimpfung-vor-allem-bei-Non-Hodgkin-Lymphom-und-aktiver-Therapie
-
Undetectable SARS-CoV-2 active adaptive immunity—post-vaccination or post-COVID-19 severe disease—after immunosuppressants use
(Hinzugefügt: 09.12.2021 um 16:56 Uhr)
https://casereports.bmj.com/content/14/11/e246308
-
Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant
(Hinzugefügt: 09.12.2021 um 16:53 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786552
-
Neutralization breadth of SARS-CoV-2 viral variants following primary series and booster SARS-CoV-2 vaccines in patients with cancer
(Hinzugefügt: 07.12.2021 um 19:37 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00614-0
-
Neutralizing Antibody Testing in Patients With Multiple Myeloma Following COVID-19 Vaccination
(Hinzugefügt: 07.12.2021 um 19:34 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2786472
-
T cells step up after SARS-CoV-2 vaccination with B cell depletion
(Hinzugefügt: 06.12.2021 um 13:44 Uhr)
https://www.nature.com/articles/s41582-021-00582-w
-
Evaluation of COVID-19 vaccine breakthrough infections among immunocompromised patients fully vaccinated with BNT162b2
(Hinzugefügt: 01.12.2021 um 18:08 Uhr)
https://www.tandfonline.com/doi/full/10.1080/13696998.2021.2002063
-
A fourth dose of the mRNA-1273 SARS-CoV-2 vaccine improves serum neutralization against the delta variant in kidney transplant recipients
(Hinzugefügt: 29.11.2021 um 07:21 Uhr)
https://www.medrxiv.org/content/10.1101/2021.11.25.21266704v1
-
Assessment of 4 Doses of SARS-CoV-2 Messenger RNA–Based Vaccine in Recipients of a Solid Organ Transplant
(Hinzugefügt: 25.11.2021 um 19:34 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2786552
-
Hybrid immunity versus vaccine-induced immunity against SARS-CoV-2 in patients with autoimmune rheumatic diseases
(Hinzugefügt: 25.11.2021 um 18:51 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00356-8/fulltext
-
Impfansprechen von Dialysepatienten auf COVID-19-Impfstoffe
(Hinzugefügt: 25.11.2021 um 18:30 Uhr)
https://www.aerzteblatt.de/nachrichten/129404/Impfansprechen-von-Dialysepatienten-auf-COVID-19-Impfstoffe
-
SARS-CoV-2 Spike-Specific T-Cell Responses in Patients With B-Cell Depletion Who Received Chimeric Antigen Receptor T-Cell Treatments
(Hinzugefügt: 20.11.2021 um 11:04 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2786409
-
Reduced antibody activity against SARS-CoV-2 B.1.617.2 Delta virus in serum of mRNA-vaccinated patients receiving Tumor Necrosis Factor-α inhibitors
(Hinzugefügt: 20.11.2021 um 11:02 Uhr)
https://www.cell.com/med/fulltext/S2666-6340(21)00378-0
-
Immunity after COVID-19 vaccinations in immunocompromised patients with psoriasis
(Hinzugefügt: 19.11.2021 um 20:19 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00360-X/fulltext
-
mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial
(Hinzugefügt: 19.11.2021 um 20:18 Uhr)
https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00574-X/fulltext
-
Humoral and cellular immunogenicity to a second dose of COVID-19 vaccine BNT162b2 in people receiving methotrexate or targeted immunosuppression: a longitudinal cohort study
(Hinzugefügt: 19.11.2021 um 20:17 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00333-7/fulltext
-
Predictors of neutralizing antibody response to BNT162b2 vaccination in allogeneic hematopoietic stem cell transplant recipients
(Hinzugefügt: 19.11.2021 um 16:53 Uhr)
https://jhoonline.biomedcentral.com/articles/10.1186/s13045-021-01190-3
-
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab
(Hinzugefügt: 19.11.2021 um 16:53 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00351-9/fulltext
-
Cellular and humoral immunity after the third dose of SARS-CoV-2 vaccine in patients treated with rituximab -
(Hinzugefügt: 19.11.2021 um 16:52 Uhr)
https://mashupmd.com/cellular-and-humoral-immunity-after-the-third-dose-of-sars-cov-2-vaccine-in-patients-treated-with-rituximab/
-
Low levels of anti-SARS-CoV-2 antibodies after vaccination in rituximab- treated patients: Comment on article of Simon et al
(Hinzugefügt: 19.11.2021 um 16:52 Uhr)
https://onlinelibrary.wiley.com/doi/10.1002/art.42011
-
COVID-19 vaccination and immunomodulatory or immunosuppressive drugs: indications and contraindications
(Hinzugefügt: 19.11.2021 um 16:50 Uhr)
https://spcare.bmj.com/content/early/2021/10/10/bmjspcare-2021-003371
-
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
(Hinzugefügt: 19.11.2021 um 16:48 Uhr)
https://acrabstracts.org/abstract/factors-associated-with-reduced-immunogenicity-of-the-bnt162b2-mrna-covid-19-vaccine-in-patients-with-autoimmune-inflammatory-rheumatic-diseases-aiird-treated-with-rituximab/
-
COVID-19 vaccine response factors identified in rituximab-treated patients
(Hinzugefügt: 19.11.2021 um 16:45 Uhr)
https://rheumatology.medicinematters.com/acr-2021/covid-19/calculator-predictor-aiird-rituximab/19847202
-
Risk factors of impaired humoral response to COVID-19 vaccination in rituximab treated patients
(Hinzugefügt: 19.11.2021 um 16:43 Uhr)
https://pubmed.ncbi.nlm.nih.gov/34726701/
-
Rituximab Frequency Could Influence Rheumatic Patient Response to COVID-19 Vaccines
(Hinzugefügt: 19.11.2021 um 16:42 Uhr)
https://www.hcplive.com/view/rituximab-frequency-rheumatic-patient-response-covid-19-vaccines
-
Rituximab Linked to Worse COVID-19 Vaccine Response than Immunosuppressants
(Hinzugefügt: 19.11.2021 um 16:41 Uhr)
https://www.hcplive.com/view/rituximab-worse-covid-19-vaccine-response-immunosuppressants
-
Covid-Impfung für Krebspatienten: Neue Daten belegen Wirksamkeit
(Hinzugefügt: 19.11.2021 um 16:05 Uhr)
https://healthcare-in-europe.com/de/news/covid-impfung-fuer-krebspatienten-neue-daten-belegen-wirksamkeit.html
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
(Hinzugefügt: 19.11.2021 um 16:02 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00278-7/fulltext
-
COVID-19: mRNA-Impfstoffe bei abwehrgeschwächten Patienten schwächer wirksam
(Hinzugefügt: 06.11.2021 um 09:34 Uhr)
https://www.aerzteblatt.de/nachrichten/128823/COVID-19-mRNA-Impfstoffe-bei-abwehrgeschwaechten-Patienten-schwaecher-wirksam
-
Diese Gruppe Menschen Wird Von MRna Impfstoffen Wie BionTech Wohl Nicht Ausreichend Geschützt!
(Hinzugefügt: 05.11.2021 um 07:32 Uhr)
https://www.androidkosmos.de/diese-gruppe-menschen-wird-von-mrna-impfstoffen-wie-biontech-wohl-nicht-ausreichend-geschuetz/
-
Uneven Covid-19 vaccine efficacy in blood cancers mean masks to stay
(Hinzugefügt: 04.11.2021 um 09:14 Uhr)
https://www.clinicaltrialsarena.com/analysis/covid-19-vaccine-boosters-efficacy-blood-cancers-masks/
-
Immunization of immunocompromised persons: Canadian Immunization Guide
(Hinzugefügt: 01.11.2021 um 09:49 Uhr)
https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-3-vaccination-specific-populations/page-8-immunization-immunocompromised-persons.html
-
Vaccines and the immunosuppressed
(Hinzugefügt: 01.11.2021 um 09:49 Uhr)
https://covid.joinzoe.com/post/vaccines-and-the-immunosuppressed
-
Effectiveness of mRNA BNT162b2 COVID-19 vaccine in immunocompromised individuals
(Hinzugefügt: 01.11.2021 um 09:48 Uhr)
https://www.news-medical.net/news/20211026/Effectiveness-of-mRNA-BNT162b2-COVID-19-vaccine-in-immunocompromised-individuals.aspx
-
Neuartiger Impfstoff gegen SARS-CoV-2 speziell für Patienten mit Krebserkrankungen und Immunschwäche in Erprobung
(Hinzugefügt: 01.11.2021 um 09:40 Uhr)
https://www.medizin.uni-tuebingen.de/de/das-klinikum/pressemeldungen/387
-
COVID-19 vaccination in patients with multiple myeloma: a consensus of the European Myeloma Network
(Hinzugefügt: 29.10.2021 um 11:40 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00278-7/fulltext
-
Was, wenn auch die dritte Corona-Impfung nicht wirkt?
(Hinzugefügt: 25.10.2021 um 07:28 Uhr)
https://www.t-online.de/nachrichten/panorama/id_91010224/leben-ohne-corona-schutz-wenn-auch-die-dritte-impfung-nicht-wirkt.html
-
Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease
(Hinzugefügt: 18.10.2021 um 10:30 Uhr)
https://www.thelancet.com/journals/langas/article/PIIS2468-1253(21)00374-5/fulltext
-
Vaccine-Induced SARS-CoV-2 Antibodies in Inflammatory Diseases
(Hinzugefügt: 16.10.2021 um 11:39 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2784976
-
WHO-Beirat empfiehlt dritte Coronaimpfdosis für Immungeschwächte
(Hinzugefügt: 12.10.2021 um 10:29 Uhr)
https://www.aerzteblatt.de/nachrichten/128087/WHO-Beirat-empfiehlt-dritte-Coronaimpfdosis-fuer-Immungeschwaechte
-
Immunological responses to SARS-CoV-2 vaccines in kidney transplant recipients
(Hinzugefügt: 06.10.2021 um 06:22 Uhr)
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02096-1/fulltext
-
Ema empfiehlt Booster-Impfungen für Immungeschwächte
(Hinzugefügt: 05.10.2021 um 09:39 Uhr)
https://www.spiegel.de/wissenschaft/medizin/corona-ema-empfiehlt-booster-impfungen-fuer-immungeschwaechte-a-b2c5b815-84ed-43f3-9a22-303aa6be2509
-
Delayed Kinetics of IgG, but not IgA, Anti-spike Antibodies in Transplant Recipients following SARS-CoV-2 Infection
(Hinzugefügt: 05.10.2021 um 09:37 Uhr)
https://jasn.asnjournals.org/content/early/2021/10/01/ASN.2021040573
-
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
(Hinzugefügt: 05.10.2021 um 08:17 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00247-2/fulltext
-
Ohne B-Zellen zum Impferfolg
(Hinzugefügt: 03.10.2021 um 08:14 Uhr)
https://www.twincore.de/infothek/infothek-news-details/news/ohne-b-zellen-zum-impferfolg/
-
Covid-19: Eingeschränkter Impferfolg nach Antikörpertherapie
(Hinzugefügt: 03.10.2021 um 08:12 Uhr)
https://idw-online.de/de/news775794
-
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
(Hinzugefügt: 03.10.2021 um 08:12 Uhr)
https://www.nature.com/articles/s41408-021-00546-9
-
COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab
(Hinzugefügt: 03.10.2021 um 08:10 Uhr)
https://www.the-rheumatologist.org/article/covid-19-vaccination-induces-t-cell-response-in-patients-treated-with-rituximab/
-
Sind SARS-CoV-2-reaktive T‑Zellen bei Patienten unter Anti-CD20-Therapie mit einer beeinträchtigten humoralen Antwort nachweisbar und potenziell protektiv?
(Hinzugefügt: 03.10.2021 um 08:09 Uhr)
https://link.springer.com/article/10.1007/s00393-021-01083-3
-
Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study
(Hinzugefügt: 03.10.2021 um 08:00 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00251-4/fulltext
-
Eingeschränkter Impferfolg nach Antikörpertherapie
(Hinzugefügt: 03.10.2021 um 08:00 Uhr)
https://www.unibe.ch/aktuell/medien/media_relations/medienmitteilungen/2021/medienmitteilungen_2021/eingeschraenkter_impferfolg_nach_antikoerpertherapie/index_ger.html
-
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
(Hinzugefügt: 02.10.2021 um 18:32 Uhr)
https://www.nature.com/articles/s41591-021-01542-z
-
Immune responses to two and three doses of the BNT162b2 mRNA vaccine in adults with solid tumors
(Hinzugefügt: 02.10.2021 um 18:23 Uhr)
https://www.nature.com/articles/s41591-021-01542-z.epdf?sharing_token=gH_YGA1XqyGeCHYo15bsptRgN0jAjWel9jnR3ZoTv0PO8tyVwy2VLV4PGGmpE9S03shbk3QlWz-mAmA7wWtShPKixwKhioDSXxcyU91b6qaTBeBP1zrWWRFeizE9g9BIf6boYRqkQkVAubxft5nuFoXGZxf5cC8O8_Vfa4XrHM0%3D
-
Humoral Immune Response in Hematooncological Patients and Health Care Workers Who Received SARS-CoV-2 Vaccinations
(Hinzugefügt: 02.10.2021 um 18:04 Uhr)
https://jamanetwork.com/journals/jamaoncology/fullarticle/2784649
-
Reduced magnitude and durability of humoral immune responses by COVID-19 mRNA vaccines among older adults
(Hinzugefügt: 29.09.2021 um 10:20 Uhr)
https://www.medrxiv.org/content/10.1101/2021.09.06.21263149v1
-
Immunocompromised patients in the USA and UK should receive third dose of COVID-19 vaccine
(Hinzugefügt: 29.09.2021 um 09:57 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00313-1/fulltext
-
QCovid® risk calculator
(Hinzugefügt: 27.09.2021 um 09:55 Uhr)
https://bmjsept2021.qcovid.org/
-
Neue Auswertungen aus Großbritannien Welche Menschen trotz Corona-Impfung schwer erkranken
(Hinzugefügt: 27.09.2021 um 09:55 Uhr)
https://www.t-online.de/gesundheit/krankheiten-symptome/id_90835116/corona-pandemie-wer-trotz-impfung-schwer-erkrankt-neue-auswertungen.html
-
Anti-CD20-Antikörpertherapie ist keine Kontraindikation für COVID-19-Impfung!
(Hinzugefügt: 24.09.2021 um 13:10 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8047585/
-
SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity FREE
(Hinzugefügt: 24.09.2021 um 13:05 Uhr)
https://ard.bmj.com/content/80/10/1345
-
Safety and Antibody Response After 1 and 2 Doses of BNT162b2 mRNA Vaccine in Recipients of Allogeneic Hematopoietic Stem Cell Transplant
(Hinzugefügt: 20.09.2021 um 09:28 Uhr)
https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2784061
-
Development of humoral and cellular immunological memory against SARS-CoV-2 despite B cell depleting treatment in multiple sclerosis
(Hinzugefügt: 20.09.2021 um 09:24 Uhr)
https://www.cell.com/iscience/fulltext/S2589-0042(21)01046-4
-
Anti-spike antibody response to SARS-CoV-2 booster vaccination in patients with B cell-derived hematologic malignancies
(Hinzugefügt: 20.09.2021 um 09:23 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00490-6
-
Rituximab und SARS-CoV-Impfung: Mit den ersten peripheren B-Zellen kommt auch die Antikörperantwort
(Hinzugefügt: 20.09.2021 um 09:21 Uhr)
https://dgn.org/neuronews/journal_club/rituximab-und-sars-cov-impfung-mit-den-ersten-peripheren-b-zellen-kommt-auch-die-antikoerperantwort/
-
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
(Hinzugefügt: 20.09.2021 um 09:20 Uhr)
https://ard.bmj.com/content/80/10/1355
-
Rituximab-induced acute lympholysis and pancytopenia after COVID-19 vaccination
(Hinzugefügt: 20.09.2021 um 09:17 Uhr)
https://onlinelibrary.wiley.com/doi/10.1002/ccr3.4517
-
COVID-19 vaccine failure in a patient on rituximab therapy
(Hinzugefügt: 20.09.2021 um 09:16 Uhr)
https://academic.oup.com/rheumap/article/5/2/rkab038/6290723
-
Antibody Responses to SARS-CoV-2 After Infection or Vaccination in Children and Young Adults With Inflammatory Bowel Disease
(Hinzugefügt: 19.09.2021 um 14:53 Uhr)
https://academic.oup.com/ibdjournal/advance-article/doi/10.1093/ibd/izab207/6371006
-
SARS-CoV-2-Impfung wirkt bei Patienten mit Immunschwächekrankheiten schwächer
(Hinzugefügt: 15.09.2021 um 15:51 Uhr)
https://www.aerzteblatt.de/nachrichten/126701/SARS-CoV-2-Impfung-wirkt-bei-Patienten-mit-Immunschwaechekrankheiten-schwaecher
-
COVID-19 and immune-mediated inflammatory diseases: effect of disease and treatment on COVID-19 outcomes and vaccine responses
(Hinzugefügt: 15.09.2021 um 15:41 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00247-2/fulltext
-
Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2FREE
(Hinzugefügt: 15.09.2021 um 15:19 Uhr)
https://www.acpjournals.org/doi/10.7326/M21-1757
-
Antibody response after third BNT162b2 dose in recipients of allogeneic HSCT
(Hinzugefügt: 15.09.2021 um 14:34 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00274-X/fulltext
-
Preexisting and Post–COVID-19 Immune Responses to SARS-CoV-2 in Patients with Cancer
(Hinzugefügt: 15.09.2021 um 14:31 Uhr)
https://cancerdiscovery.aacrjournals.org/content/11/8/1982
-
SARS-CoV-2-Impfung wirkt bei Patienten mit Immunschwächekrankheiten schwächer
(Hinzugefügt: 14.09.2021 um 07:26 Uhr)
https://www.aerzteblatt.de/nachrichten/126701/SARS-CoV-2-Impfung-wirkt-bei-Patienten-mit-Immunschwaechekrankheiten-schwaecher
-
Impact of rituximab on humoral response to COVID-19 booster vaccine and antibody kinetics in patients with ANCA vasculitis
(Hinzugefügt: 14.09.2021 um 07:25 Uhr)
https://www.kidney-international.org/article/S0085-2538(21)00839-5/fulltext
-
Pandemie erfordert Neubewertung der antirheumatischen Therapeutika
(Hinzugefügt: 14.09.2021 um 07:24 Uhr)
https://www.rosenfluh.ch/media/congressselection/2021/07/COVID-19-und-Rheuma-Pandemie-erfordert-Neubewertung-der-antirheumatischen-Therapeutika.pdf
-
Ohne B-Zellen zum Impferfolg
(Hinzugefügt: 14.09.2021 um 07:23 Uhr)
https://www.twincore.de/infothek/infothek-news-details/news/ohne-b-zellen-zum-impferfolg/
-
SARS-CoV-2-Impfung wirkt bei Patienten mit Immunschwächekrankheiten schwächer
(Hinzugefügt: 28.08.2021 um 13:44 Uhr)
https://www.aerzteblatt.de/nachrichten/126701/SARS-CoV-2-Impfung-wirkt-bei-Patienten-mit-Immunschwaechekrankheiten-schwaecher
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial
(Hinzugefügt: 26.08.2021 um 04:22 Uhr)
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00157-0/fulltext
-
Antibody development after COVID-19 vaccination in patients with autoimmune diseases in the Netherlands: a substudy of data from two prospective cohort studies
(Hinzugefügt: 26.08.2021 um 04:16 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00222-8/fulltext
-
Humoral and cellular immune responses in SARS-CoV-2 mRNA-vaccinated patients with cancer
(Hinzugefügt: 26.08.2021 um 04:05 Uhr)
https://www.sciencedirect.com/science/article/pii/S1535610821004414
-
Examining the Immunological Effects of COVID-19 Vaccination in Patients with Conditions Potentially Leading to Diminished Immune Response Capacity – The OCTAVE Trial
(Hinzugefügt: 26.08.2021 um 04:03 Uhr)
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3910058
-
COVID-19 vaccine response in people with multiple sclerosis
(Hinzugefügt: 24.08.2021 um 16:17 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.31.21261326v1
-
Coronavirus (COVID-19) Update: FDA Authorizes Additional Vaccine Dose for Certain Immunocompromised Individuals
(Hinzugefügt: 14.08.2021 um 09:02 Uhr)
https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-additional-vaccine-dose-certain-immunocompromised
-
Patients treated with anti-CD20 therapy can mount robust T cell responses to mRNA-based COVID-19 vaccines
(Hinzugefügt: 03.08.2021 um 09:49 Uhr)
https://www.medrxiv.org/content/10.1101/2021.07.21.21260928v1
-
Are Immunocompromised Patients Left Out by COVID Vaccines?
(Hinzugefügt: 03.08.2021 um 09:16 Uhr)
https://www.cuimc.columbia.edu/news/are-immunocompromised-patients-left-out-covid-vaccines
-
Humoral and cellular immunity to SARS-CoV-2 vaccination in renal transplant versus dialysis patients: A prospective, multicenter observational study using mRNA-1273 or BNT162b2 mRNA vaccine
(Hinzugefügt: 28.07.2021 um 12:39 Uhr)
https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(21)00155-1/fulltext
-
Transplant patients’ higher rate of COVID-19 breakthroughs boosts case for booster vaccines
(Hinzugefügt: 27.07.2021 um 19:26 Uhr)
https://www.sciencemag.org/news/2021/07/transplant-patients-higher-rate-covid-19-breakthroughs-boosts-case-booster-vaccines
-
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
(Hinzugefügt: 20.07.2021 um 10:52 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00212-5/fulltext
-
Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study
(Hinzugefügt: 20.07.2021 um 10:49 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMoa2102685
-
CDC warns Covid-19 vaccines might not protect people who are immunocompromised
(Hinzugefügt: 19.07.2021 um 11:58 Uhr)
https://edition.cnn.com/2021/07/16/health/cdc-warning-covid-19-vaccine-immunocompromised/index.html
-
Auch ohne B-Zellen zum Impferfolg gegen COVID-19
(Hinzugefügt: 17.07.2021 um 13:42 Uhr)
https://innovationorigins.com/de/auch-ohne-b-zellen-zum-impferfolg-gegen-covid-19/
-
CDC advisers to consider additional coronavirus dose for immunocompromised patients
(Hinzugefügt: 17.07.2021 um 13:17 Uhr)
https://www.washingtonpost.com/health/2021/07/15/covid-booster-shots-immunocompromised/
-
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
(Hinzugefügt: 09.07.2021 um 19:18 Uhr)
https://immunology.sciencemag.org/content/6/60/eabj1031
-
Implications of defective immune responses in SARS-CoV-2 vaccinated organ transplant recipients
(Hinzugefügt: 09.07.2021 um 19:16 Uhr)
https://immunology.sciencemag.org/content/6/61/eabj6513
-
The effect of methotrexate and targeted immunosuppression on humoral and cellular immune responses to the COVID-19 vaccine BNT162b2: a cohort study
(Hinzugefügt: 09.07.2021 um 19:07 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00212-5/fulltext
-
SARS-CoV-2: Einige Krebstherapeutika machen Impfung unwirksam
(Hinzugefügt: 09.07.2021 um 18:35 Uhr)
https://www.aerzteblatt.de/nachrichten/125381/SARS-CoV-2-Einige-Krebstherapeutika-machen-Impfung-unwirksam
-
Immunogenicity of COVID-19 Vaccination in Immunocompromised Patients: An Observational, Prospective Cohort Study Interim Analysis
(Hinzugefügt: 03.07.2021 um 17:55 Uhr)
https://www.medrxiv.org/content/10.1101/2021.06.28.21259576v1
-
The Challenge of Covid-19 Vaccines for the Immunosuppressed
(Hinzugefügt: 30.06.2021 um 15:41 Uhr)
https://www.wired.com/story/the-challenge-of-covid-19-vaccines-for-the-immunosuppressed/
-
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
(Hinzugefügt: 30.06.2021 um 15:41 Uhr)
https://www.acpjournals.org/doi/10.7326/L21-0282
-
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
(Hinzugefügt: 30.06.2021 um 15:40 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777685
-
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
(Hinzugefügt: 30.06.2021 um 15:40 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2779852
-
Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients
(Hinzugefügt: 30.06.2021 um 15:39 Uhr)
https://www.kireports.org/article/S2468-0249(21)01130-X/fulltext#%20
-
COVID-19 Vaccine in the Immunocompromised Study (CoVICS)
(Hinzugefügt: 30.06.2021 um 15:38 Uhr)
https://www.upmc.com/coronavirus/monoclonal-antibodies/covics-study
-
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case SeriesFREE
(Hinzugefügt: 30.06.2021 um 15:37 Uhr)
https://www.acpjournals.org/doi/full/10.7326/M21-1451
-
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
(Hinzugefügt: 30.06.2021 um 15:36 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.05.21254656v2
-
Seasonal influenza vaccine in immunocompromised persons
(Hinzugefügt: 30.06.2021 um 15:35 Uhr)
https://pubmed.ncbi.nlm.nih.gov/29485353/
-
COVID-19 vaccine responses to be studied in people with immune deficits
(Hinzugefügt: 30.06.2021 um 15:35 Uhr)
https://www.nih.gov/news-events/news-releases/covid-19-vaccine-responses-be-studied-people-immune-deficits
-
Three Doses of an mRNA Covid-19 Vaccine in Solid-Organ Transplant Recipients
(Hinzugefügt: 30.06.2021 um 15:17 Uhr)
https://www.nejm.org/doi/full/10.1056/NEJMc2108861
-
Protecting The Immuno-Compromised Against COVID Could Be Key To Ending The Pandemic
(Hinzugefügt: 30.06.2021 um 14:51 Uhr)
https://www.npr.org/sections/goatsandsoda/2021/06/28/1011043650/the-key-to-ending-the-pandemic-may-be-protecting-immunocompromised-people
-
Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
(Hinzugefügt: 30.06.2021 um 14:42 Uhr)
https://www.thelancet.com/journals/lanmic/article/PIIS2666-5247(21)00157-9/fulltext
-
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
(Hinzugefügt: 30.06.2021 um 14:33 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00336-6
-
Highly variable SARS-CoV-2 spike antibody responses to two doses of COVID-19 RNA vaccination in patients with multiple myeloma
(Hinzugefügt: 30.06.2021 um 14:33 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00336-6
-
The Challenge of Covid-19 Vaccines for the Immunosuppressed
(Hinzugefügt: 23.06.2021 um 17:54 Uhr)
https://www.wired.com/story/the-challenge-of-covid-19-vaccines-for-the-immunosuppressed/
-
Immunogenicity of a Single Dose of SARS-CoV-2 Messenger RNA Vaccine in Solid Organ Transplant Recipients
(Hinzugefügt: 23.06.2021 um 17:53 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2777685
-
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
(Hinzugefügt: 23.06.2021 um 17:53 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2779852
-
Postvaccine Anti–SARS-CoV-2 Spike Protein Antibody Development in Kidney Transplant Recipients
(Hinzugefügt: 23.06.2021 um 17:52 Uhr)
https://www.kireports.org/article/S2468-0249(21)01130-X/fulltext#%20
-
Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
(Hinzugefügt: 23.06.2021 um 17:52 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.06.21254949v1
-
COVID-19 Vaccine in the Immunocompromised Study (CoVICS)
(Hinzugefügt: 23.06.2021 um 17:51 Uhr)
https://www.upmc.com/coronavirus/monoclonal-antibodies/covics-study
-
Antibody response to a single dose of SARS-CoV-2 mRNA vaccine in patients with rheumatic and musculoskeletal diseases FREE
(Hinzugefügt: 23.06.2021 um 17:51 Uhr)
https://ard.bmj.com/content/early/2021/03/23/annrheumdis-2021-220289
-
Absence of Humoral Response After Two-Dose SARS-CoV-2 Messenger RNA Vaccination in Patients With Rheumatic and Musculoskeletal Diseases: A Case SeriesFREE
(Hinzugefügt: 23.06.2021 um 17:50 Uhr)
https://www.acpjournals.org/doi/full/10.7326/M21-1451
-
High antibody response to two-dose SARS-CoV-2 messenger RNA vaccination in patients with rheumatic and musculoskeletal diseases FREE
(Hinzugefügt: 23.06.2021 um 17:50 Uhr)
https://ard.bmj.com/content/early/2021/05/23/annrheumdis-2021-220656
-
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
(Hinzugefügt: 23.06.2021 um 17:50 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.05.21254656v2
-
Seasonal influenza vaccine in immunocompromised persons
(Hinzugefügt: 23.06.2021 um 17:49 Uhr)
https://pubmed.ncbi.nlm.nih.gov/29485353/
-
COVID-19 vaccine responses to be studied in people with immune deficits
(Hinzugefügt: 23.06.2021 um 17:49 Uhr)
https://www.nih.gov/news-events/news-releases/covid-19-vaccine-responses-be-studied-people-immune-deficits
-
Safety and Immunogenicity of a Third Dose of SARS-CoV-2 Vaccine in Solid Organ Transplant Recipients: A Case Series
(Hinzugefügt: 20.06.2021 um 17:56 Uhr)
https://www.acpjournals.org/doi/10.7326/L21-0282
-
Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial
(Hinzugefügt: 20.06.2021 um 10:45 Uhr)
https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(21)00103-X/fulltext
-
Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients
(Hinzugefügt: 20.06.2021 um 10:39 Uhr)
https://immunology.sciencemag.org/content/6/60/eabj1031.full
-
Immunogenicity of SARS-CoV-2 messenger RNA Vaccines in Patients with Cancer
(Hinzugefügt: 20.06.2021 um 10:38 Uhr)
https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00330-5
-
SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases
(Hinzugefügt: 14.06.2021 um 05:34 Uhr)
https://ard.bmj.com/content/early/2021/05/05/annrheumdis-2021-220461
-
'Breakthrough' COVID Infections May Be Common in Vaccinated Transplant Patients
(Hinzugefügt: 09.06.2021 um 19:14 Uhr)
https://www.usnews.com/news/health-news/articles/2021-06-08/breakthrough-covid-infections-may-be-common-in-vaccinated-transplant-patients
-
SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response
(Hinzugefügt: 27.05.2021 um 12:13 Uhr)
https://ard.bmj.com/content/early/2021/05/05/annrheumdis-2021-220408
-
Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS- CoV-2 vaccination in patients with rheumatic diseases
(Hinzugefügt: 27.05.2021 um 12:08 Uhr)
https://ard.bmj.com/content/early/2021/05/10/annrheumdis-2021-220604
-
Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’
(Hinzugefügt: 27.05.2021 um 12:04 Uhr)
https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220382
-
Response to: ‘Correspondence on ‘Second COVID-19 infection in a patient with granulomatosis with polyangiitis on rituximab’’ by Tampe et al FREE
(Hinzugefügt: 27.05.2021 um 12:00 Uhr)
https://ard.bmj.com/content/early/2021/05/11/annrheumdis-2021-220398
-
Preexisting and post-COVID-19 immune responses to SARS-CoV-2 in cancer patients
(Hinzugefügt: 22.05.2021 um 18:05 Uhr)
https://cancerdiscovery.aacrjournals.org/content/early/2021/05/14/2159-8290.CD-21-0191.article-info
-
There are more immunocompromised Americans than we think, and that’s a problem with COVID-19 vaccines
(Hinzugefügt: 22.05.2021 um 17:23 Uhr)
https://www.popsci.com/health/immunocompromised-covid-19-vaccine/
-
Covid vaccines may not protect people with immune disorders. NIH trial seeks answers.
(Hinzugefügt: 15.05.2021 um 10:15 Uhr)
https://www.nbcnews.com/health/health-news/covid-vaccines-may-not-protect-people-immune-disorders-nih-trial-n1266886
-
Teils mehrere Impfversuche Impfantwort bei Autoimmunkranken gestört
(Hinzugefügt: 13.05.2021 um 17:26 Uhr)
https://www.n-tv.de/wissen/Impfantwort-bei-Autoimmunkranken-gestoert-article22550735.html
-
Methotrexate Hampers Immunogenicity to BNT162b2 mRNA COVID-19 Vaccine in Immune-Mediated Inflammatory Disease
(Hinzugefügt: 13.05.2021 um 17:09 Uhr)
https://www.medrxiv.org/content/10.1101/2021.05.11.21256917v1
-
Single dose of BNT162b2 mRNA vaccine against SARS-CoV-2 induces high frequency of neutralising antibody and polyfunctional T-cell responses in patients with myeloproliferative neoplasms
(Hinzugefügt: 12.05.2021 um 07:47 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.27.21256096v1
-
Infection and Immune Memory: Variables in Robust Protection by Vaccines Against SARS-CoV-2
(Hinzugefügt: 12.05.2021 um 07:46 Uhr)
https://www.frontiersin.org/articles/10.3389/fimmu.2021.660019/full
-
Warum sich Leukämie-Patienten gegen Covid impfen lassen sollen
(Hinzugefügt: 11.05.2021 um 07:16 Uhr)
https://www.presseportal.de/pm/42657/4912047
-
Vaccination Against COVID 'Does Not Mean Immunity' For People With Organ Transplants
(Hinzugefügt: 08.05.2021 um 12:25 Uhr)
https://www.npr.org/sections/health-shots/2021/05/07/994260770/vaccination-against-covid-does-not-mean-immunity-for-people-with-organ-transplan
-
COVID-19: Organtransplantierte auch nach 2. Impfdosis nicht sicher geschützt
(Hinzugefügt: 08.05.2021 um 12:24 Uhr)
https://www.aerzteblatt.de/nachrichten/123704/COVID-19-Organtransplantierte-auch-nach-2-Impfdosis-nicht-sicher-geschuetzt
-
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
(Hinzugefügt: 06.05.2021 um 09:43 Uhr)
https://jamanetwork.com/journals/jama/fullarticle/2779852
-
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
(Hinzugefügt: 04.05.2021 um 13:34 Uhr)
https://www.sciencedirect.com/science/article/pii/S1470204521002138?via%3Dihub
-
Impaired immunogenicity of BNT162b2 anti SARS-CoV-2 vaccine in patients treated for solid tumors.
(Hinzugefügt: 04.05.2021 um 13:34 Uhr)
https://www.sciencedirect.com/science/article/pii/S0923753421011832?via%3Dihub
-
Some patients do not develop immunity after covid vaccination
(Hinzugefügt: 04.05.2021 um 05:31 Uhr)
https://sundhedspolitisktidsskrift.dk/nyheder/4792-nogle-patienter-udvikler-ikke-immunitet-efter-covid-vaccination.html
-
Auch STIKO empfiehlt, bei eingeschränkter Immunabwehr zu impfen
(Hinzugefügt: 02.05.2021 um 03:17 Uhr)
https://www.pharmazeutische-zeitung.de/rheuma-ist-keine-kontraindikation-122964/seite/2/
-
Relief and worry for immune-suppressed people
(Hinzugefügt: 30.04.2021 um 05:44 Uhr)
https://science.sciencemag.org/content/372/6541/443.full
-
COVID19 Impfung bei MS-Patienten mit Immuntherapien – neue Daten aus Israel
(Hinzugefügt: 29.04.2021 um 07:40 Uhr)
https://www.ms-docblog.de/multiple-sklerose/covid19-impfung-bei-ms-patienten-mit-immuntherapien-neue-daten-aus-israel/
-
In-Depth: A potential vaccine substitute for people with compromised immune systems?
(Hinzugefügt: 29.04.2021 um 07:10 Uhr)
https://www.10news.com/news/in-depth/in-depth-a-potential-vaccine-substitute-for-people-with-compromised-immune-systems
-
COVID-19 vaccines may not offer complete protection for people with compromised immune systems
(Hinzugefügt: 29.04.2021 um 07:10 Uhr)
https://abcnews.go.com/Health/covid-19-vaccines-offer-complete-protection-people-compromised/story?id=77248931
-
Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study
(Hinzugefügt: 28.04.2021 um 19:53 Uhr)
https://www.thelancet.com/action/showPdf?pii=S1470-2045%2821%2900213-8
-
COVID-19 Vaccination of Immunocompromised Patients Manual
(Hinzugefügt: 22.04.2021 um 12:56 Uhr)
https://lci.rivm.nl/handleiding-covid-19-vaccinatie-van-immuungecompromitteerde-patienten
-
ESMO STATEMENTS FOR VACCINATION AGAINST COVID-19 IN PATIENTS WITH CANCER
(Hinzugefügt: 22.04.2021 um 12:55 Uhr)
https://www.esmo.org/covid-19-and-cancer/covid-19-vaccination
-
Managing patients with rheumatic diseases treated with rituximab during the COVID-19 pandemic
(Hinzugefügt: 22.04.2021 um 12:55 Uhr)
https://www.thelancet.com/journals/lanrhe/article/PIIS2665-9913(21)00077-1/fulltext
-
More advice on vaccines for immunocompromised patients
(Hinzugefügt: 22.04.2021 um 12:53 Uhr)
https://www1.racgp.org.au/newsgp/clinical/more-advice-on-covd-vaccines-for-immunocompromised
-
Response to first vaccination against SARS-CoV-2 in patients with multiple myeloma
(Hinzugefügt: 21.04.2021 um 06:01 Uhr)
https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(21)00110-1/fulltext
-
Blunted vaccines responses after ocrelizumab highlight need for immunizations prior to treatment
(Hinzugefügt: 19.04.2021 um 08:43 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7897403/pdf/main.pdf
-
Impact of Biological Therapies on the Immune Response after Pneumococcal Vaccination in Patients with Autoimmune Inflammatory Diseases
(Hinzugefügt: 19.04.2021 um 08:42 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7997274/pdf/vaccines-09-00203.pdf
-
COVID-19 vaccination and antirheumatic therapy
(Hinzugefügt: 19.04.2021 um 08:36 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7989162/
-
Comment on “An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology”
(Hinzugefügt: 19.04.2021 um 08:35 Uhr)
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7965843/
-
An Immune Recovery-Based Revaccination Protocol for Pediatric Hematopoietic Stem Cell Transplant Recipients: Revaccination Outcomes Following Pediatric HSCT
(Hinzugefügt: 19.04.2021 um 08:33 Uhr)
https://www.sciencedirect.com/science/article/pii/S2666636721006242?via%3Dihub
-
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2
(Hinzugefügt: 18.04.2021 um 07:50 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.05.21254656v2
-
General Principles of COVID-19 Vaccines for Immunocompromised Patients
(Hinzugefügt: 17.04.2021 um 09:51 Uhr)
https://www.hematology.org/covid-19/ash-astct-covid-19-and-vaccines
-
People With Blood Cancer May Not Be Optimally Protected After mRNA COVID-19 Vaccination
(Hinzugefügt: 17.04.2021 um 09:50 Uhr)
https://scitechdaily.com/people-with-blood-cancer-may-not-be-optimally-protected-after-mrna-covid-19-vaccination/
-
People With Blood Cancer May Not Be Optimally Protected After mRNA COVID-19 Vaccination
(Hinzugefügt: 17.04.2021 um 09:50 Uhr)
https://www.nytimes.com/2021/04/15/health/coronavirus-vaccine-immune-system.html
-
Distinct antibody and memory B cell responses in SARS-CoV-2 naïve and recovered individuals following mRNA vaccination
(Hinzugefügt: 17.04.2021 um 09:48 Uhr)
https://immunology.sciencemag.org/content/6/58/eabi6950.full
-
Suboptimal response to COVID-19 mRNA vaccines in hematologic malignancies patients
(Hinzugefügt: 08.04.2021 um 13:18 Uhr)
https://www.medrxiv.org/content/10.1101/2021.04.06.21254949v1
-
NEUARTIGER IMPFSTOFF ZUR AKTIVIERUNG VON T-ZELL-ANTWORTEN GEGEN SARS-COV-2 IN ERPROBUNG – IMPFSTUDIE STARTET
(Hinzugefügt: 08.04.2021 um 13:17 Uhr)
https://dgfi.org/neuartiger-impfstoff-zur-aktivierung-von-t-zell-antworten-gegen-sars-cov-2-in-erprobung-impfstudie-startet/
-
Rheumatologen aktualisieren Empfehlungen zu Therapie und COVID-19-Impfung
(Hinzugefügt: 06.04.2021 um 07:26 Uhr)
https://www.aerzteblatt.de/nachrichten/121656/Rheumatologen-aktualisieren-Empfehlungen-zu-Therapie-und-COVID-19-Impfung
-
COVID-19 and Indolent Lymphomas: Frequently Asked Questions
(Hinzugefügt: 06.04.2021 um 07:22 Uhr)
https://www.hematology.org/covid-19/covid-19-and-indolent-lymphomas
-
What information is there on COVID-19 vaccination?
(Hinzugefügt: 06.04.2021 um 07:20 Uhr)
https://www.rheumatology.org.uk/practice-quality/covid-19-guidance